+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06059638

Evaluating AV Interval Modulation Therapy Using Medtronic AstraAzure Dual-Chamber Pacemaker for Hypertension Treatment

Led by Orchestra BioMed, Inc · Updated on 2026-10-02

316

Participants Needed

131

Research Sites

139 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new atrioventricular interval modulation AVIM algorithm programmed into a dual-chamber Medtronic AstraAzure pacemaker. This trial is designed to assess the safety and effectiveness of this device-based therapy in patients who have hypertension and either already have or need a dual-chamber pacemaker. The study is randomized, double-blind, and conducted across multiple countries. The study has three phases an initial screening phase, followed by a one-year double-blind randomized phase where participants are assigned to either have the AVIM therapy turned on or off, while continuing their stable antihypertensive medication. After this, there is a two-year unblinded phase for further observation. The investigational AVIM therapy is delivered through the pacemaker device. Participants will be monitored for changes in their 24-hour ambulatory systolic blood pressure and for any unexpected serious adverse effects related to the device. Assessments will be done at baseline and three months after randomization, with ongoing evaluation during the two-year follow-up. The entire study duration can last up to three years, including screening and all treatment phases.

CONDITIONS

Brief Title

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

Research Team

S

Steven J. Evans, MD

A

Angela Stagg

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here